SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jnc12264-sup-0001-FigS1-S2.docWord document203K

Figure S1. Troglitazone does not alter the phosphorylation states of tau at other sites such as Thr212, Ser262, and Ser396 in SH-SY5Y cells.

Figure S2. Roscovitine, a CDK5 inhibitor, further decreases tau-Thr231 phosphorylation and p35 expression remained in the troglitazone-treated SH-SY5Y cells.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.